2013 CTN Web Seminar Series

Produced by: NIDA CTN CCC Training Office"This training has been funded in whole or in part with Federal funds from the National Institute on Drug Abuse,

National Institutes of Health, Department of Health and Human Services, under Contract No.HHSN271201000024C."

DEVELOPING MEDICATION ASSISTED TREATMENT (MAT)

PROTOCOLSPresented by:

Andrew J. Saxon, MD

July 17, 2013

2

Objectives:• Consider some of the prior medication assisted

treatment protocols conducted in the CTN for lessons learned.

• Identify design decisions that need to be made concerning medication assisted treatment protocols, including considerations about blinding and adherence strategies.

• Describe regulatory aspects of medication assisted treatment protocols.

3

Trial

Med Treatment

Drug Product

Placebo

Treatment as usual

DESIGNING MEDICATION ASSISTED PROTOCOLS

4

Specific Topics to Consider• Investigational New Drug Application (NDA) from

FDA?• Open label or blinded MAT trial?• Placebo or active comparator?• Dosing strategy—Fixed or flexible?• Adherence strategy?• More exclusive or more inclusive enrollment

criteria?• What, if any, behavioral platform?• Safety monitoring plan

5

REGULATORY CONSIDERATIONS

6

IND• An Investigator IND is submitted by a physician

who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed.  A physician might submit a research IND to propose studying an unapproved drug, or an approved product for a new indication or in a new patient population.

7

IND• CDER's

Pre-Investigational New Drug Application (IND) Consultation Program5 fosters early communications between sponsors and new drug review divisions to provide guidance on the data necessary to warrant IND submission. The review divisions are organized generally along therapeutic class and can each be contacted using the designated Pre-IND Consultation List (PDF - 19KB)6.

8

IND Examples• Injectable risperidone for methamphetamine

dependence– Drug company sponsor – wanted IND– Use in new population – FDA requested IND

• Prazosin for Alcohol Dependence– University/NIH sponsor – no position on IND– Given widespread use of prazosin, has probably been

used by patients with AUD– No plans to seek a change in labeling or advertising– Exempt from IND

9

Controlled Substances

• Obtain appropriate DEA licensure

• Obtain licensure specific to each state

10

BLINDING AND PLACEBO STRATEGIES

11

Open Label vs. Blinded Study

Enck et al., 2013

12

Open Label Advantages• Good for pilot studies to test:

– tolerability– safety– possibly dose effects

• More real world• For some medications expectancies are

component of efficacy– Disulfiram (Antabuse)

• Less complex/costly

13

Blinding Advantage• Accounts for expectancy effects

– Patients– Research staff

• Double blind vs. single blind

Benedetti et al., 2005

15

Placebo Response

Benedetti et al., 2005

16

Placebo vs. Active Comparator• If active medication has profound, observable

effects, inert placebo may break blind

• Active “placebo” possible

• If an already approved medication for indication exists, head to head comparison informative

17

PRIOR MEDICATION ASSISTED TREATMENT PROTOCOLS

Lessons Learned in the CTN

18

START Study Schema1920 Number screened for participation

1269 Randomized

740 Buprenorphine/Naloxone 529 Methadone

340 Evaluable400 Failed to remain on assigned

medication for 24 wks0 Failed to provide ≥ 4 LT

samples

391 Evaluable 136 Failed to remain on assigned

medication for 24 wks2 Failed to provide ≥ 4 LT samples

261 Completed 32-week follow-up 330 Completed 32-week follow-up

19

CTN 0028 OROS-Methylphenidate ADHD/SUD

Riggs et al., 2011

Titrated to 72 mg per day

CTN 0048 CURB Study Schema

20

21

Fixed vs. Flexible Dosing• Fixed dosing

– requires less physician time– Fixed dosing may miss optimum dose

• Flexible dosing– Titrate to effects/side effects– Need algorithm to guide study physician– More real world– More complex analytic approach may be needed

22

CTN 0003 Buprenorphine TaperTaper Group Total

7 day taper 28 day taper

Stabilization Dose

8 mg 22 26 48 (9.3%)

16 mg 68 73 141 (27.3%)

24 mg 165 162 327 (63.4%)

Total 255 (49.4%) 261 (50.6%) 516 (100%)

23

ADHERENCE STRATEGIES

24

Potential Adherence Measures• Observed dosing• Pill counts• Biologic marker• Electronic monitoring• Self report• Plasma or urine drug concentrations

25

PRIOR MEDICATION ASSISTED TREATMENT PROTOCOLS

Lessons Learned in the CTN

26

0053 Achieving Cannabis Cessation - Evaluating N-Acetylcysteine Treatment (ACCENT)

• The primary objective is to evaluate impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to compliance enhancement (CE) and contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults.

• Medication adherence will be assessed using self-report, blister pack pill counts, and urine riboflavin testing.

27

0052 Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC)

28

0052 Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC)

• The primary objective is to evaluate the efficacy of buspirone, relative to placebo, in preventing relapse in cocaine-dependent adults in inpatient/residential treatment who are planning to enter outpatient treatment upon inpatient/residential discharge.

• MEMS, pill count, and participant self-report of medication adherence will be collected.

• Urine samples will be shipped to a central lab, and samples from the buspirone group will be assayed for buspirone and/or its metabolite.

29

MEMS• The Medication Event Monitoring System, (MEMS) is a

medication bottle cap with a microprocessor that records the occurrence and time of each bottle opening.

30

INCLUSION/EXCLUSION STRATEGIES

31

Enrollment Criteria• More restrictive

– Increase safety– Possibly increase likelihood of effect

• Less restrictive– Increase generalizability– Interventions found efficacious in clinical trials often

fail in real world

32

PRIOR MEDICATION ASSISTED TREATMENT PROTOCOLS

Lessons Learned in the CTN

33

Exclusions 0027 START

• ALT or AST values > 5 times the upper limit of normal

• Known diagnosis of acute psychosis, severe depression or imminent suicide risk

• Poor venous access such that venipuncture could not be accomplished from a vein in an extremity during eligibility

34

Exclusions 0052 BRAC• Medical or psychiatric condition that, in the

judgment of the study physician, would make study participation unsafe or which would make treatment compliance difficult. Medical conditions that may compromise participant safety or study conduct include, but are not limited to: – AIDS – liver function tests greater than 3X upper limit of normal – serum creatinine greater than 2 mg/dL

• Psychiatric disorder requiring continued treatment with a psychotropic medication

35

Potential Behavioral Platforms• Medications alone not expected to be fully

efficacious for SUD

• More intensive behavioral intervention– Could overwhelm medication effects– Could provide sufficient support and/or synergy to

allow medication to work• Less intensive behavioral intervention

– Less likely to overwhelm medication effects– May not hold patients in treatment sufficiently to

allow medication to work

36

PRIOR MEDICATION ASSISTED TREATMENT PROTOCOLS

Lessons Learned in the CTN

37

Behavioral Interventions from CTN MAT Trials

• Bup Taper and START – Counseling as usual

• OROS-methylphenidate ADHD/SUD– CBT (highly efficacious)

• ACCENT– compliance enhancement (CE) and contingency

management (CM)

38

CTN 0028 OROS-Methylphenidate ADHD/SUD

Riggs et al., 2011

39

SAFETY MONITORING

40

Safety Monitoring

• Data Safety Monitoring Board– Established for CTN MAT Trials

• Plan to assess adverse events and serious adverse events

• Laboratory monitoring– e.g., liver tests, glucose, CBC

• Cardiac monitoring– ECG

41

Recap / Highlights

• Designing MAT trials involves numerous decision points and trade-offs

• MAT trials conducted in CTN can provide considerable guidance in making these decisions for design of future MAT trials

42

Q&A – Questions / Comments

Alternatively, questions can be directed to the presenter by sending an email to CTNtraining@emmes.com.

43

References• Saxon et al., Buprenorphine/Naloxone and methadone

effects on laboratory indices of liver health: A randomized trial. Drug and Alcohol Dependence 128:71-76, 2013.

• Riggs et al., Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention deficit/hyperactivity disorder and substance use disorders. Journal of the American Academy of Child & Adolescent Psychiatry 50:903-914, 2011.

• Ling et al., Buprenorphine tapering schedule and illicit opioid use. Addiction 104:256-265, 2009.

44

Survey Reminder

Upcoming Webinar

The NIDA CCC encourages all to complete the survey issued to participants directly following this webinar session. Watch for the email notification!

Also, please visit the Training Suggestion Box to post general comments: https://www.surveymonkey.com/s/CTNTrainingSuggestionBox

Social Media – Using Social Media as a Clinical Trials Research Tool

Wednesday, August 21, 20131:00 pm to 2:00 pm ET

45

A copy of this presentation will be available electronically after this session.

http://ctndisseminationlibrary.org

46

Thank you for participating.NIDA CTN Web Seminar Series